Technology ID

Treatment of Alcoholism by Inhibition of the Neuropeptide Y Receptor

Lead Inventor
Heilig, Markus (Office of Research Services (ORS))
Therapeutic Areas
Development Status
Early stage
Lead IC
Aversive or anticraving medications are currently used to supplement behavioral treatment of alcohol dependence. However, there is a need for developing more effective medications than those available. Neuropeptide Y (NPY) is a neurotransmitter known for increasing appetite and possibly having a role in alcohol preference and dependence. This is likely to be mediated by activation of the post-synaptic NPY-Y1 receptor, but developing molecules suitable for human therapeutics that activate that receptor represents a major challenge. Researchers at the NIH have now shown that administering antagonists of the presynaptic Y2 receptor of NPY decreases alcohol consumption and may be a valuable new treatment for alcoholism.
Commercial Applications
Treatment of alcohol dependence

Licensing Contact:
Specialist (ALS), Admin. Licensing